A search for serologic correlates of immunity to Bordetella pertussis cough illnesses

Vaccine

Volumn 16, Issue 20, 1998, Pages 1901-1906

  Cherry, James D ^a   Gornbein, Jeffrey ^b   Heininger, Ulrich ^c   Stehr, Klemens ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

B. pertussis immunity; Immunity to pertussis; Pertussis vaccine; Serologic correlates of immunity

Indexed keywords

ANTIBODY; BACTERIAL ANTIGEN; HEMAGGLUTININ; IMMUNOGLOBULIN G; PERTACTIN; PERTUSSIS TOXIN; PERTUSSIS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BORDETELLA PERTUSSIS; CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EXPOSURE; FIMBRIA; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INFANT; INFECTION PREVENTION; INFECTION RISK; PERTUSSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SEROLOGY;

ADHESINS, BACTERIAL; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL PROTEINS; BIOLOGICAL MARKERS; COHORT STUDIES; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DOUBLE-BLIND METHOD; FEMALE; FIMBRIAE PROTEINS; FIMBRIAE, BACTERIAL; HEMAGGLUTININS; HUMANS; IMMUNOGLOBULIN G; INFANT; MALE; MULTIVARIATE ANALYSIS; PERTUSSIS TOXIN; PERTUSSIS VACCINE; PROSPECTIVE STUDIES; VIRULENCE FACTORS, BORDETELLA; WHOOPING COUGH;

EID: 0032374233     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00226-6     Document Type: Article

References (32)

1. 1 Cherry, J. Historical review of pertussis and the classical vaccine. J. Infect Dis. 1996, 174(Suppl3), S259-S263.
2. 2 Cherry, J.D., Brunell, P.A., Golden, G.S. and Darzon, D.T. Report of the task force on pertussis and pertussis immunization - 1988. Pediatrics 1988, 81, 939-984.
3. 3 Medical Research Council. Vaccination against whooping cough: relation between protection in children and results of laboratory tests. Br. Med. J. 1956, 2, 454-462.
4. 4 Miller, J.J. Jr., Silverberg, R.J., Saito, T.M. and Number, J.B. An agglutinative reaction for Hemophilus pertussis: II. Its relation to clinical immunity. J. Pediatr. 1943, 22, 644-651.
5. 5 Sako, W. Studies on pertussis immunization. J. Pediatr, 1947, 30, 29.
6. 6 Stehr, K., Cherry, J.D., Heininger, U. et al. and the Pertussis Vaccine Study Group. A comparative efficacy trial in Erlangen, Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine or DT vaccine. Pediatrics 1998, 101, 1-11.
7. 7 Heininger, U., Cherry, J., Stehr, K. et al. and the Pertussis Vaccine Study Group. Comparative efficacy of the Lederle/ Takeda acellular pertussis component DTP (DTaP) vaccine and the Lederle whole-cell component DTP vaccine in German children following household exposure. Pediatrics 1998, 102, 546-553.
8. 8 Ad Hoc Group for the Study of Pertussis Vaccines. Placebo-controlled trial of two acellular pertussis vaccines in Sweden-protective efficacy and adverse events. Lancet 1988, 1, 955-960.
9. 9 Storsaeter, J., Blackwelder, W.C. and Hallander, H.O. Pertussis antibodies, protection, and vaccine efficacy after household exposure. AJDC 1992, 146, 167-172.
10. 10 Storsaeter, J., Hallander, H., Farrington, C.P., Olin, P., Möllby, R. and Miller, E. Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial. Vaccine 1990, 8, 457-461.
11. 11 Schmitt, H.J., Wirsing von König, C.H. and Neiss, A. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996, 275, 37-41.
12. 12 Greco, D., Salmaso, S., Biol, D. et al. and the Progetto Pertosse Working Group. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N. Engl. J. Med. 1996, 334, 341-348.
13. 13 Gustafsson, L., Hallander, H.O., Olin, P., Reizenstein, E. and Storsaeter, J. A controlled trial of two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med. 1996, 334, 349-355.
14. 14 Trollfors, B., Taranger, J. and Lagergård, T. et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N. Engl. J. Med. 1995, 333, 1045-1050.
15. 15 Simondon, F., Preziosi, M.P. and Yam, A. et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 1997, 15, 1606-1612.
16. 16 Liese, J.G., Meschievitz, C.K., Harzer, E. et al. and the Munich Pertussis Study Group. Efficacy of a two-component acellular pertussis vaccine in infants. Pediatr Infect Dis J. 1997, 16, 1038-1044.
17. 17 Trollfors, B., Taranger, J. and Lagergård, T. et al. Efficacy of a monocomponent pertussis toxoid vaccine after household exposure to pertussis. J. Pediatr. 1997, 130, 532-536.
18. 18 Olin, P., Rasmussen, F., Gustafsson, L., Hallander, H.O. and Heijbel, H. For the Ad Hoc Group for the Study of Pertussis Vaccines. Lancet 1997, 350, 1569-1578.
19. 19 Deen, J.L., Mink, C.M. and Cherry, J.D. et al. Household contact study of Bordetella pertussis infections. Clin. Inf. Dis. 1995, 21, 1211-1219.
20. 20 Storsaeter, J.H., Hallander, H.O., Gustafsson, L. and Olin, P. Levels of antipertussis antibodies over time related to protection after household exposure to Bordetella pertussis. Vaccine 1998, 16, 1907-1916.
21. 21 Heininger, U., Cherry, J.D., Eckhardt, T., Lorenz, C., Christenson, P. and Stehr, K. Clinical and laboratory diagnosis of pertussis in the regions of a large vaccine efficacy trial in Germany. Pediatr. Infect. Dis. J. 1993, 12, 504-509.
22. 22 Schläpfer, G., Cherry, J.D. and Heininger, U. et al. Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany. J. Ped. Inf. Dis. 1995, 14, 209-214.
23. 23 Manclark, C.R., Meade, B.D. and Burstyn, D.G. Serologic response to Bordetella pertussis. In: Manual of Clinical Laboratory Immunology (Eds Rose, N.R., Friedman, H. and Fahey, J.L), 3rd ed. American Society for Microbiology, Washington, D.C, 1986, pp. 388-394.
24. 24 Heininger, U., Cherry, J.D. and Christenson, P.D. et al. Comparative study of Lederle/Takeda acellular and Lederle whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants in Germany. Vaccine 1994, 12, 81-86.
25. 25 Cherry, J.D. and Heninger, U. Pertussis and other bordetella infections. In: Textbook of Pediatric Infectious Diseases (Eds Feigin, R.D. and Cherry, J.D.), 4th ed. W.B. Saunders Co., Philadelphia, PA, 1998, pp. 1423-1440.
26. 26 Cherry, J.D. Pertussis: the trials and tribulations of old and new pertussis vaccines. Vaccine 1992, 10, 1033-1037.
27. 27 Pitman, M. Pertussis toxin: the cause of the harmful effects and prolonged immunity of whooping cough. A hypothesis. Rev. Infect. Dis. 1979, 1, 401-402.
28. 28 Hewlett, E.L. and Cherry, J.D. New and improved vaccines against pertussis. In: New Generation Vaccines (Eds Levine, M.M., Woodrow, G.C., Kaper, J.B. and Cobon, G.S.) 2nd Edition. Marcel Dekker, Inc., New York, 1997, pp. 387-416.
29. 29 Cherry, J.D., Heininger, U. and Christenson, P.D. et al. Surrogate serologic tests for the prediction of pertussis vaccine efficacy. New York Academy of Sciences 1995, 754, 359-363.
30. 30 Cherry, J.D. Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials. Pediatr. Infect. Dis. J. 1997, 16, S90-S96.
31. 31 Cherry, J.D., Heininger, U., Stehr, K. and Christenson, P. The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial. Pediatrics in press.
32. 32 Olin, P. Commentary: the best acellular pertussis vaccines are multicomponent. Pediatr. Infect. Dis. J. 1997, 16, 517-519.